T7455
Tolvaptan
≥98% (HPLC), V2-selective antagonist, powder
别名:
N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide, OPC 41061
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C26H25ClN2O3
化学文摘社编号:
分子量:
448.94
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
产品名称
Tolvaptan, ≥98% (HPLC), powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to tan
solubility
DMSO: ≥15 mg/mL
originator
Sanofi Aventis
storage temp.
2-8°C
SMILES string
Cc1ccccc1C(=O)Nc2ccc(c(C)c2)C(=O)N3CCCC(O)c4cc(Cl)ccc34
InChI
1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
InChI key
GYHCTFXIZSNGJT-UHFFFAOYSA-N
Gene Information
human ... AVPR2(554)
Application
Tolvaptan has been used as a V2-selective antagonist for studying its effect on hypertension in mice.
Biochem/physiol Actions
Tolvaptan (OPC 41061) is a potent, orally active non-peptide vasopressin V2 selective antagonist. IC50 = 3 nM at the rat V2 receptor; 29 times more selective for the V2 than for V1a. Tolvaptan has also been shown to inhibit the development of polycystic kidney disease in several animal models.
Tolvaptan is a potent, orally active non-peptide vasopressin V2 receptor antagonist.
Features and Benefits
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Preparation Note
Tolvaptan is soluble in DMSO at a concentration that is greater than or equal to 15 mg/ml.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| T7455-25MG | 04061837373152 |
| T7455-5MG | 04061832868769 |